Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature

Niesert, A.; Gürtler, A.; Schutti, O.; Engels, L.; Flaig, M.; French, L.; Schlaak, M. und Reinholz, M. (2021): Ulcerated Lichen Planus after Adjuvant Use of Programmed Cell Death-1-Inhibitor: A Case Report and Systematic Review of the Literature. In: Acta Dermato-Venereologica, Bd. 101, adv00472

Abstract

Over the past 6 years, programmed cell death-1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) antibodies have become the first-line treatments for advanced skin tumours (1). PD-1 and PD-L1 antibodies gradually garnered first- and later-line Food and Drug Administration (FDA) approvals for multiple indications, such as non-small cell lung cancer (NSCLC), renal cell carcinoma, urothelial carcinoma, colorectal and hepatocellular carcinoma, Hodgkin's lymphoma and, most recently, oesophageal cancer (2). Due to their overall good tolerance and appealing clinical outcome, nivolumab and pembrolizumab have also been approved for adjuvant therapy of malignant melanoma since July 2018 (3). In addition, various clinical trials are investigating the adjuvant use of PD-1 and PD-L1 antibodies in other tumour entities (4-6). Due to the increasing prescription of these drugs, various, previously unknown, immune-related adverse events (irAE) are gaining importance in everyday clinical practice, including cutaneous side-effects in up to 40% of treated patients (7). Thus, patients receiving the treatment in an adjuvant setting deserve profound information and require a thorough riskbenefit assessment before initiation of the therapy.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 0001-5555
• Sprache: Englisch